Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

particularly if you keep them up after stopping the drug. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps balance blood sugar (glucose) levels, suppresses appetite ...

In August 2024, Eli Lilly reduced the price of its GLP-1 Zepbound by almost 50% to compete with knock-offs. It now sells for $399 to $549 a month ... of semaglutide in May 2022. After she achieved ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was ... patients who have not lost more than 5% of weight after six months of treatment. Considering the SELECT trial report ...

Courtesy Staci Rice, Classified as a GLP-1, appetite-suppressing medications, semaglutide is the active ... come and I wouldn’t take it.” After a few months without the drugs, her “food ...